Biotherapeutics

Discussion in 'Smith & Nephew' started by anonymous, Feb 14, 2017 at 4:18 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I am interviewing for a biotherapeutics position. Has anyone ever sold in biotherapeutics and then been able to move to device sales?

    I would rather not ask that question during an interview and figured I could get some feedback here.
     

  2. anonymous

    anonymous Guest

    Yes and they regretted the decision soon after for many reasons. Until quality leadership is in place, stay away. The Device VP is not someone to follow or trust.
     
  3. anonymous

    anonymous Guest

    Seriously - do you think you can get a straight/honest answer on this board? This board is for people to complain about SNN, not to try to help people with career advice. That being said, I will be captain obvious here but first will call you a dumbsh*t for asking your question without considering this possibility. Maybe biotherapeutics is not your launching pad for device sales with another company, but it can be within SNN. Consistently make your number selling biotherapeutics, and you should have the opportunity to take a position selling medical devices at another SNN division. It's not a stretch for somebody to go from selling biotherapeutics to selling PICO, which is a medical device within Wound. Just remember not to tell the manager you are interviewing with your plan - why would she hire you if she knew that this was a transition position for you.
     
  4. anonymous

    anonymous Guest

    You are a complete idiot if you join SNN.
     
  5. anonymous

    anonymous Guest

    Thanks for the response. That's why I asked the question here. I know that's not a question for the interview. There are some companies that make it difficult to move from one division to another so it's good to know that there are people who have done well in biotherapeutics and moved on to device sales. Pico sounds like a good product from the little I've read.
     
  6. anonymous

    anonymous Guest

    Biotherapeutics is definitely the most 'talented' division at S&N. As far as the earlier comments; it is possible to use the success in Biotherapeutics to transfer divisions internally - but the Wound division supporting PICO is in shambles. High turnover, mediocre pay, unrealistic sales expectations, poor leadership - you name it. As far as transferring externally - I suppose on what it is you desire to do. I always considered the Bio job to be similar to a Pharma job, but it's certainly possible to make the move if successful.
     
  7. anonymous

    anonymous Guest

    The Bio Job is a slam dunk. Product has a monopoly. If you enjoy being a food caterer along with handing out data and a few sound bites then it is terrific.
     
  8. anonymous

    anonymous Guest

    Thanks for the replies.

    Since Santyl and Regranex are old, is there anything interesting to talk about?

    Seems like Santyl has monopoly but is anyone really happy talking about it? I just find it hard to believe that you can significantly increase sales on a product that's been out this long.
     
  9. anonymous

    anonymous Guest

    you can talk about the handful of accounts where you'll be asked to maintain and/or grow Oasis. To the comment above - it is pretty spot on. You'll be a lunch great little lunch caterer.
     
  10. anonymous

    anonymous Guest

    I am soo thankful to have Oasis in my bag. Gives me something new to talk about. Pretty easy to sell and seems like the accounts really love it. Should make some good money this year with it.
     
  11. anonymous

    anonymous Guest

    Sounds like McCann trolling again. Oasis has been around for over a decade. The spots you're calling on are going to be driven by reimbursement. They'll use passthru code products to maximize reimbursement dollars. Oasis doesn't do much to address that piece. We get killed on reimbursement. I don't think they're giving all the crap accounts to Biotherapeutics with the hope that you all will turn the ship around lol.

     
  12. anonymous

    anonymous Guest

    Market demands are high for a lower cost skin substitute one that can be stored on the shelf with accessibility to the practioners. The operating room is looking for a replacement to Integra and Oasis can meet their needs
     
  13. anonymous

    anonymous Guest

    Sales don't support this meritless argument Bud. We've heard that for years yet Oasis sales continue to erode. So much so that's its an oversight in whomever's bag you put it in.

     
  14. anonymous

    anonymous Guest

    If customers are using other products on large wounds they are losing out. Oasis should be their choice along with Santyl.
     
  15. anonymous

    anonymous Guest

    I see the brainwashing game is still strong here. When I was with at this godforsaken company, KS in training told me that Santyl cures cancer. SMH
     
  16. anonymous

    anonymous Guest


    Aaaaaah yes a mindless turd of a rep that knows more than a trained doctor.....where o where would we be without fucktards like you educating us on extremely old technology....please just shut up and bring me donuts and coffee in the morning
     
  17. anonymous

    anonymous Guest

    The market has shifted back from the flashy skin substitutes to the gold standard Oasis with the most RCT available. GPOs are recognizing this and putting parameters in place. Great year to be an Oasis representative
     
  18. anonymous

    anonymous Guest

    Gold standard is not Oasis!!! Last I heard the gold standard was a autograft then allograft then xenografts....I guess your the wound care expert here though.
     
  19. anonymous

    anonymous Guest

    Nothing out there has more data along with ease of use and cost savings.
     
  20. anonymous

    anonymous Guest

    Ease of use? Come on now child I have yet to see any graft that was complex. I can tell you one thing there are several other products with far more data that is significantly superior. Oasis is used by lazy DPM's that use it for superficial wounds.